SC
IDXX icon

Stance Capital’s Idexx Laboratories IDXX Stock Holding History

Stance Capital’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$211K Hold
400
– – 0.06% 139
2026
Q1 		$225K Hold
400
– – 0.11% 95
2025
Q4 		$271K Sell
400
-6,587
-94% -$4.49M 0.1% 131
2025
Q3 		$4.46M Buy
6,987
+5,252
+303% +$3.19M 1.64% 9
2025
Q2 		$931K Buy
+1,735
New +$830K 0.35% 138
2025
Q1 		– Sell
-406
Closed -$168K – 156
2024
Q4 		$168K Buy
+406
New +$178K 0.1% 110

Other funds holding IDXX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BAMCO Inc
BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Stance Capital's IDXX Position: Q2 2026 in Review

Stance Capital held its Idexx Laboratories (IDXX) position steady in Q2 2026 at 400 shares worth $211K. The position accounts for 0.06% of the portfolio, ranked #139.

Stance Capital first reported a position in IDXX in Q4 2024 and has held it in 6 quarters since. The position peaked at $4.46M in Q3 2025. 1,302 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Stance Capital held 400 shares of Idexx Laboratories worth $211K as of Q2 2026.
  • Stance Capital left its Idexx Laboratories share count unchanged in Q2 2026.
  • Idexx Laboratories made up 0.06% of Stance Capital's portfolio in Q2 2026, its #139 holding.
  • Stance Capital first reported a position in Idexx Laboratories in Q4 2024 and has held it in 6 quarters since.
  • Stance Capital's Idexx Laboratories position peaked at $4.46M in Q3 2025.
  • 1,302 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Stance Capital's 13F filing for Q2 2026, filed 14 Aug 2026.